ZEVALIN

LOE Approaching

ibritumomab tiuxetan

BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT00807196Phase 1/2Unknown

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Started Sep 2008
20 enrolled
Non-Hodgkins Lymphoma
NCT01448928N/ACompleted

Zevalin Post-marketing Surveillance in Japan

Started Sep 2008
400 enrolled
Non-Hodgkin's Lymphoma (NHL)
NCT01479387N/ACompleted

Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan

Started Aug 2008
72 enrolled
Non-Hodgkin's Lymphoma (NHL)
NCT00607854Phase 2Completed

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Started Feb 2008
31 enrolled
Diffuse Large B-Cell LymphomaMantle Cell Lymphoma
NCT01164696N/ACompleted

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Started Aug 2007
30 enrolled
Lymphoma, FollicularNon-Hodgkin Lymphoma